FORTIUS

*Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia, alone or with risk factors for myopathy orrhabdomyolysis, or with risk of cardiovascular events:* Adult: Initially 5-10 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks. Children10-18 yrs: initially 5 mg daily, increased if necessary at intervals of at least 4 wk to usual, max 20 mg once daily. *Prevention of cardiovascular events in patients at high risk of a first cardiovascular event:* Adult: 20 mg once daily. Adult 70 years and over: Initially 5 mg once daily; then increased if necessary up to 20 mg once daily.

Severe renal impairment. Active liver disease including elevated serum transaminases, myopathy, risk of renal failure secondary to rhabdomyolysis, hypothyroidism, history of hereditary muscle disorders, history of muscle toxicity with a statin or fibrate, alcohol abuse.

Severe hepatic impairment, history of liver disease. Monitor liver function before and 3 months after starting treatment, Advise patients to report unexplained muscle weakness or pain; monitor creatine kinase levels, renal impairment, elderly (more than 70 years).

Gemfibrozil, fibrates, nicotinic acid, cyclosporin, azole antifungals, protease inhibitors, macrolides, warfarin, antacids, oral contraceptives.

Proteinuria, Gynaecomastia, haematuria, oedema, Stevens-Johnson syndrome, headache, dizziness, GI upset, myalgia, anaesthesia.